Stručni rad

The efficacy and safety of ramipril as monotherapy and in fixed-dose combination with hydrochlorothiazide in the treatment of different groups of hypertensive patients and its effect on cardiovascular prevention

Saša Žikić ; Krka, d.d., Movo mesto, Slovenija
Mateja Grošelj ; Krka, d.d., Novo mesto, Slovenija
Breda Barbič-Žagar orcid.org/0000-0002-1173-7361 ; Krka, d.d., Novo mesto, Slovenija

Sažetak

Hypertension is a major health problem in
the world. One in every three adults has high blood pressure
(BP). The excessive pressure on the artery walls caused by high
BP can damage blood vessels, as well as organs in the body.
Uncontrolled high BP can lead to different complications. Hypertension
is accompanied by cardiovascular risk factors, such
as diabetes, previous myocardial infarction or stroke, dyslipidemia,
obesity or proven vascular disease, in at least twothirds
of all cases. Today’s treatment of hypertension is very
challenging, especially in patients with enhanced cardiovascular
risk, where a multiple pharmacological approach is often
required to achieve an acceptable BP goal. Ramipril is a
lipophilic ACE inhibitor suitable for once-daily administration.
It effectively reduces peripheral vascular resistance, thus regulating
high BP. In combination with hydrochlorothiazide, it
produces a synergetic effect, which increases the efficacy and
safety of both drugs. Ramipril has been studied in numerous
clinical studies. Also the efficacy and safety of Krka’s ramipril
(Ampril®) have been studied in several clinical and post-authorisation
safety and efficacy studies. Krka’s ramipril is offered in
a variety of dosage forms, strengths and fixed-dose combinations

Ključne riječi

hypertension; angiotensin-converting enzyme inhibitor; ramipril

Hrčak ID:

71840

URI

https://hrcak.srce.hr/71840

Datum izdavanja:

20.9.2011.

Podaci na drugim jezicima: hrvatski

Posjeta: 1.314 *